



December 22, 2014

Amicus Therapeutics Added to NASDAQ Biotechnology Index (NBI)

CRANBURY, N.J., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the [NASDAQ Biotechnology Index](#) (Nasdaq:NBI) (Nasdaq:XBNI), effective prior to the market open on December 22, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. The NASDAQ Biotechnology Index is the basis for the [iShares NASDAQ Biotechnology Index Fund \(IBB\)](#), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

Eligibility criteria include a minimum market capitalization of \$200 million, and an average daily volume of at least 100,000 shares. For more information about the NASDAQ Biotechnology Index please visit <https://indexes.nasdaqomx.com/Index/Overview/NBI>.

About Amicus Therapeutics

[Amicus Therapeutics](#) (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone [migalastat](#) as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.

FOLD-G

CONTACT: Investors:

Sara Pellegrino

Director, Investor Relations

spellegrino@amicusrx.com

(609) 662-5044



Source: Amicus Therapeutics, Inc.

News Provided by Acquire Media